



COLORADO

Department of Health Care
Policy & Financing

**AGENDA: DUR BOARD MEETING
Colorado Medicaid DUR
Department of Health Care Policy and Financing**

Skaggs School of Pharmacy and Pharmaceutical Sciences Building
12850 East Montview Blvd, Aurora CO 80045
Seminar Room- Room 1000; First floor
Parking available in the Henderson/Visitor Parking Garage

February 16, 2016
6:00 p.m. Closed Executive Session for Board Members
7:00 p.m. – 9:00 p.m. Open Session

DUR BOARD MEMBERS and CO DUR MEMBERS

LeWayne Garrison, MD
Karen Weber, DO
James 'Rick' Kant, RPh
Pam Reiter, PharmD
Edra Weiss, MD
Sheila Botts, PharmD
Mark Boesen, PharmD, JD
Kerstin Froyd, MD
Jim Regan, MD

Robert Lodge, PharmD
Robert L Page, PharmD, MSPH
(CO DUR)
Nila Mahyari, PharmD (CO DUR)
Jon Campbell, PhD (CO DUR)
Gina Moore, PharmD

1. Executive Session (Closed)

- Board member terms
- Approval of the minutes from the previous meeting
- Policy Updates: 300 MED Limit; Multiple Sclerosis overview
- CPACK and Pain Specialist Consults
- Review Retro-DUR reports
- Quarterly Drug Utilization Reports
- FDA updates
- Module Update

2. Open Session (Open to public)

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.
www.colorado.gov/hcpf



3. Introduction of Board members

4. Announcement of Board Member Term Limits

5. Approval of the minutes from the November 2015 meeting

6. Rules

- Agenda items must be approved in advance, including requests to present information. Please contact Robert Lodge at (303) 866-3105 if you want to add an agenda item. Visitors are welcome during the open portion of the meeting only.
- Anyone wishing to provide testimony must contact the DUR Coordinator Robert Lodge (Robert.Lodge@state.co.us) at 303-866-3105 or at least 24 hours before the meeting.

7. Criteria Discussion

A. Unfinished Business and General Orders

Update on the following (Update of criteria implemented January 1, 2016):

- Antiemetics
- New Generation Antidepressants
- Anti-Herpetic Agents
- Oral Anti-Platelet
- Oral Fluoroquinolones
- Pancreatic Enzymes
- Proton Pump Inhibitors
- Pulmonary Arterial Hypertension Agents
- Targeted Immune Modulators
- Triptans

B. New Business

Proposed Criteria for current PDL:

- Alzheimer's agents
- Atypical antipsychotics
- Growth hormones
- Insulin
- Intranasal corticosteroids
- Leukotriene modifiers
- Multiple Sclerosis agents
- Ophthalmic allergy

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.
www.colorado.gov/hcpf



- Sedative/hypnotics (non-benzodiazepine)
- Statins and Statin combinations

Proposed Criteria for Other Agents:

- Hepatitis C Criteria Update (full criteria review will still be at August DUR meeting)
 - Small clarifications of criteria
- Xerese (acyclovir/hydrocortisone) Criteria
- Viberzi (eluxadoline) Criteria
- Veltassa (patiomer) Criteria
- Update of Targeted Immune Modulator Criteria
 - Addition of new indications

8. Adjourn

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at 303- 866-3105 or robert.lodge@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

